AstraZeneca Buys Priority Review Voucher With Two Big Filings On The Horizon
AstraZeneca paid $95m to Swedish Orphan Biovitrum for the voucher, which it could use to expedite the FDA review of roxadustat or trastuzumab deruxtecan.
You may also be interested in...
Ruud Dobber oversees AstraZeneca’s biopharmaceuticals division, which generates some 40% of group total revenues. He tells Scrip to “Watch this space.”
Buying two vaccines for rabies and tick-borne encephalitis complements the recently approved smallpox and monkeypox vaccine Jynneos. Now the Danish firm needs to start selling them.
Keeping Track: A Novel Approval For Fluorodopa F 18, A Tentative Approval For Vumerity, And A Missed Goal Date For Zilretta
The latest drug development news and highlights from our US FDA Performance Tracker.